Our study identifies NF1 loss and activating RAS mutations as bona fide clinically relevant causes of ALK inhibitor resistance in ALK-driven neuroblastoma and establishes reactivation of signaling downstream from the RAS-MAPK pathway as a mechanism of ALK inhibitor resistance. The gene discussed is ALK; the disease is neuroblastoma.